Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial
Nicolas Marincek, Piotr Radojewski, Rebecca A Dumont, Philippe Brunner, Jan Müller-Brand, Helmut R Maecke, Matthias Briel, Martin A Walter, Nicolas Marincek, Piotr Radojewski, Rebecca A Dumont, Philippe Brunner, Jan Müller-Brand, Helmut R Maecke, Matthias Briel, Martin A Walter
Abstract
Meningiomas express members of the somatostatin receptor family. The present study assessed the long-term benefits and harm of somatostatin-based radiopeptide therapy in meningioma patients.
Methods: Patients with progressive unresectable meningioma were treated with (90)Y-DOTATOC and (177)Lu-DOTATOC until tumor progression or permanent toxicity occurred. Multivariable Cox regression analyses were used to study predictors of survival.
Results: Overall, 74 treatment cycles were performed on 34 patients. Stable disease was achieved in 23 patients. Severe hematotoxicity occurred in 3 patients, and severe renal toxicity in 1 patient. Mean survival was 8.6 y from the time of recruitment. Stable disease after treatment (hazard ratio, 0.017 vs. progressive disease; 95% confidence interval, 0.001-0.35; n = 34; P = 0.01) and high tumor uptake (hazard ratio, 0.046 vs. intermediate or low tumor uptake; 95% confidence interval, 0.004-0.63; n = 34; P = 0.019) were associated with longer survival.
Conclusion: (90)Y-DOTATOC and (177)Lu-DOTATOC are promising tools for treating progressive unresectable meningioma, especially in cases of high tracer uptake in the tumor.
Keywords: metabolic therapy; sstr2; survival; targeted therapy.
© 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Source: PubMed